» Articles » PMID: 34333624

Lifestyle, Cardiometabolic Disease, and Multimorbidity in a Prospective Chinese Study

Overview
Journal Eur Heart J
Date 2021 Aug 1
PMID 34333624
Citations 101
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: The potential difference in the impacts of lifestyle factors (LFs) on progression from healthy to first cardiometabolic disease (FCMD), subsequently to cardiometabolic multimorbidity (CMM), and further to death is unclear.

Methods And Results: We used data from the China Kadoorie Biobank of 461 047 adults aged 30-79 free of heart disease, stroke, and diabetes at baseline. Cardiometabolic multimorbidity was defined as the coexistence of two or three CMDs, including ischaemic heart disease (IHD), stroke, and type 2 diabetes (T2D). We used multi-state model to analyse the impacts of high-risk LFs (current smoking or quitting because of illness, current excessive alcohol drinking or quitting, poor diet, physical inactivity, and unhealthy body shape) on the progression of CMD. During a median follow-up of 11.2 years, 87 687 participants developed at least one CMD, 14 164 developed CMM, and 17 541 died afterwards. Five high-risk LFs played crucial but different roles in all transitions from healthy to FCMD, to CMM, and then to death. The hazard ratios (95% confidence intervals) per one-factor increase were 1.20 (1.19, 1.21) and 1.14 (1.11, 1.16) for transitions from healthy to FCMD, and from FCMD to CMM, and 1.21 (1.19, 1.23), 1.12 (1.10, 1.15), and 1.10 (1.06, 1.15) for mortality risk from healthy, FCMD, and CMM, respectively. When we further divided FCMDs into IHD, ischaemic stroke, haemorrhagic stroke, and T2D, we found that LFs played different roles in disease-specific transitions even within the same transition stage.

Conclusion: Assuming causality exists, our findings emphasize the significance of integrating comprehensive lifestyle interventions into both health management and CMD management.

Citing Articles

Joint assessment of abdominal obesity and non-traditional lipid parameters for primary prevention of cardiometabolic multimorbidity: insights from the China health and retirement longitudinal study 2011-2018.

Lai H, Tu Y, Liao C, Zhang S, He L, Li J Cardiovasc Diabetol. 2025; 24(1):109.

PMID: 40057762 PMC: 11890515. DOI: 10.1186/s12933-025-02667-y.


Lifestyles and their relative contribution to biological aging across multiple-organ systems: Change analysis from the China Multi-Ethnic Cohort study.

Zhang Y, Tang D, Zhang N, Xiang Y, Hu Y, Qian W Elife. 2025; 13.

PMID: 40052974 PMC: 11888596. DOI: 10.7554/eLife.99924.


The Construction and Application of a Clinical Decision Support System for Cardiovascular Diseases: Multimodal Data-Driven Development and Validation Study.

Miao S, Ji P, Zhu Y, Meng H, Jing M, Sheng R JMIR Med Inform. 2025; 13:e63186.

PMID: 40029975 PMC: 11892944. DOI: 10.2196/63186.


Effect of PM and its constituents on hospital admissions for cardiometabolic multimorbidity in Urumqi, China.

Wu D, Li C, Shi Y, Han J, Lu Y, Yilihamu Y Sci Rep. 2025; 15(1):6394.

PMID: 39984684 PMC: 11845472. DOI: 10.1038/s41598-025-90789-4.


Association of accelerated phenotypic aging, genetic risk, and lifestyle with progression of type 2 diabetes: a prospective study using multi-state model.

Pan L, Liu Y, Huang C, Huang Y, Lin R, Wei K BMC Med. 2025; 23(1):62.

PMID: 39901253 PMC: 11792689. DOI: 10.1186/s12916-024-03832-y.